We have detected that you are using some form of ad-blocking or filtering.
Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.
Copyright 2010 Elsevier Inc. All rights reserved.
Released March 26, 2019